“We believe that these solutions that simplify management of the therapy will enable clinicians to reduce pain or severe spasticity symptoms for even more patients with this proven therapy,” said Charlie Covert, vice president and general manager of the Targeted Drug Delivery business, which is part of the Restorative Therapies Group at Medtronic.